ResearcherUniversity of Alabama at BirminghamNo recent work listed

Andres Forero

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1360-1695; OpenAlex author ID A5046549002. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2013: 1 paper

Papers 1

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in… Co-author DOI 10.1002/cam4.137 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Selwyn Maurice Vickers · 1 shared paper, 2013 · strength 0.03
- Paper Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death recept… DOI 10.1002/cam4.137 ↗
Lucas Wong · 1 shared paper, 2013 · strength 0.03
- Paper Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death recept… DOI 10.1002/cam4.137 ↗
Aiwu Ruth He · 1 shared paper, 2013 · strength 0.03
- Paper Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death recept… DOI 10.1002/cam4.137 ↗
Mansoor Noorali Saleh · 1 shared paper, 2013 · strength 0.03
- Paper Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death recept… DOI 10.1002/cam4.137 ↗
Jeffrey R. Infante · 1 shared paper, 2013 · strength 0.03
- Paper Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death recept… DOI 10.1002/cam4.137 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.